Meitheal Pharmaceuticals has Bortezomib for Injection Now Available.
Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Bortezomib for Injection, 3.5 mg per vial in a 10 mL single-dose vial.
Meitheal will offer Bortezomib for Injection in a carton of 1 vial.
ABOUT BORTEZOMIB FOR INJECTION
Bortezomib for Injection is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and treatment of adult patients with mantle cell lymphoma. For full prescribing information and safety information, please click on the following link.
Learn more about who we are and what we do at: www.meithealpharma.com.